Coeliac Plexus vs Splanchnic Nerve Neurolysis for Upper Abdominal Cancer Pain
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorBangladesh Medical University
About this trial
The goal of this clinical trial is to determine whether Neurolytic Splanchnic Nerve Block (NSNB) reduces pain in adults with upper abdominal malignancies. It will also evaluate the safety of Neurolytic Splanchnic Nerve Block (NSNB). The main questions it aims to answer are:
Does NSNB reduce pain intensity compared to Neurolytic Coeliac Plexus Block (NCPB), as measured by the Visual Analog Scale (VAS)? What adverse effects do participants experience when receiving Neurolytic Splanchnic Nerve Block (NSNB)?
Investigators will compare Neurolytic Splanchnic Nerve Block (NSNB) with Neurolytic Coeliac Plexus Block (NCPB) to determine which intervention provides more effective and safer pain relief.
Participants will:
* receive either NSNB or NCPB under fluoroscopic guidance * be monitored immediately and for 2 hours after the procedure for any complications Have their pain intensity recorded immediately after the procedure, and at 7 days, 1 month, and 3 months * be evaluated for quality-of-life using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 3 (EORTC QLQ-C30) at 1 month and 3 months. * have their opioid consumption tracked throughout the study.
Eligibility criteria
Qualifiers
Adult patient
Both genders
Diagnosed case of upper abdominal malignancy (pancreatic, gastric, hepatic, or biliary origin)
Experiencing moderate to severe pain (≥5 on a 10 point visual analog scale)
Disqualifiers
Previous coeliac plexus block, splanchnic nerve block, or major abdominal nerve ablation
Severe spinal deformities or anatomical distortion at the coeliac plexus or splanchnic nerve site
Local or systemic infection at or near the block site
Known allergy to local anesthetics or neurolytic agents
Trial design
Treatments tested in this trial
- Neurolytic Coeliac Plexus Block (NCPB)
- Neurolytic Splanchnic Nerve Block (NSNB)
Treatment groups
44 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov